Study wrapper · #1331
Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.
Editor's note
This is the rare human in vivo look at a peptide most often discussed in community settings, and the dose-series design with a within-subject comparison makes the erythema finding more credible than a single-dose observation would be. The limits are substantial: nine participants, all phototype II-III, no control group and no blinding, an unavoidably fixed order (pre then post), and a minimal erythema dose shift that did not reach significance. The dissociation between a 2 to 3 percent instrument-measured melanin rise and unchanged histological staining is the most interesting loose end — it suggests the reduced redness may be more anti-inflammatory than pigmentary, which is a hypothesis the study is too small to settle. Note this used a licensed 16 mg implant under controlled UV exposure, which bears little resemblance to unregulated injectable use.
Plain-language abstract
Nine healthy adults were given a graded series of UVB doses on one buttock, then received a 16 mg afamelanotide implant — the licensed form of the peptide often called melanotan-1 — and six days later had the same UVB series applied to the other side. Sunburn redness across the dose range fell measurably after the implant, and instrument-measured melanin density rose by roughly 2 to 3 percent. Notably, melanin staining in skin biopsies did not change, so the redness reduction is not obviously explained by pigment alone. The authors read this as early in-human support for an anti-inflammatory action seen previously in cell studies.